[The use of thymalin in the combined treatment of patients with disseminated cancer of the cervix uteri].
Vishnevskaia. E E EE; Khavinson. V Kh VKh; Nikolaeva. D V DV
Key Findings
- Thymalin immunotherapy combined with radiotherapy showed better outcomes than radiotherapy alone
- Patients receiving thymalin were eligible for more extensive radical surgery
- The combined approach improved results in cases previously considered incurable
Practical Outcomes
- The study suggests thymalin might boost the effectiveness of radiation in advanced cervical cancer, but the data are limited to a specific cancer type and small patient groups. For self‑directed health optimizers, it’s a hint that thymalin could have immune‑supportive effects in oncology, yet it isn’t ready for broad, off‑label use without further clinical evidence.
Summary
Adding the peptide thymalin to standard radiotherapy helped women with very large cervical cancers do better – they could have more aggressive surgery and had improved treatment results compared to radiotherapy alone.
Abstract
The paper discusses results of treatment of advanced (over 100 cm in size) cervical carcinoma. Fifty-eight females of the control group received complex split-course radiotherapy whereas in 38 patients of the study group radiation was supplemented with thymalin immunotherapy at the first and second stages. The results showed the latter therapeutic modality to offer clear advantage over radiotherapy alone, viz. it allowed wider application of radical surgery and assured better results of treatment of patients previously considered incurable.
Study Information
pubmed
1991